RU-28306

RU-28306
Clinical data
Other names	RU28306
Drug class	Serotonin receptor agonist; Serotonin 5-HT1 and 5-HT2 receptor agonist; Simplified/partial LSD analogue
Identifiers
	IUPAC name N,N-dimethyl-1,3,4,5-tetrahydrobenzo[cd]indol-4-amine;
CAS Number	73625-11-3 ;
PubChem CID	194528;
ChemSpider	168785;
UNII	CT4LCW2PLE;
CompTox Dashboard (EPA)	DTXSID90994429 ;
Chemical and physical data
Formula	C13H16N2
Molar mass	200.285 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c13c(C2)cccc1[nH]cc3CC2N(C)C;
	InChI InChI=1S/C13H16N2/c1-15(2)11-6-9-4-3-5-12-13(9)10(7-11)8-14-12/h3-5,8,11,14H,6-7H2,1-2H3; Key:BQOANWOQEHVATQ-UHFFFAOYSA-N;

RU-28306 is a synthetic indole alkaloid derivative which acts as a serotonin receptor agonist, with selectivity for 5-HT₁ and 5-HT₂ subtypes. It can be regarded as a conformationally restricted tricyclic derivative of DMT or a structurally simplified derivative of LSD. The binding affinity of racemic RU-28306 is closer to that of DMT than LSD, though with relatively higher affinity for 5-HT₂ subtypes and lower for 5-HT₁. It has been sold as a designer drug and was first reported to the EMCDDA by a forensic laboratory in Slovenia in 2017. It was subsequently patented by Delix Therapeutics in 2021.